PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (23rd June 2022) - Fonseca, R.; Kuroda, J.; Ishida, T.; Popat, R.; Huang, J. S.; Yver, A.; Vandendries, E.; Elmeliegy, M.; Ma, W. D.; Sborov, D. W.